Humacyte, Inc. announced that the U.S. Department of Defense has appropriated funds under the FY 2026 National Defense Authorization Act to support the evaluation and procurement of its Symvess® bioengineered human vessels for treating traumatic extremity arterial injuries in service members. The appropriation, part of the DoD’s FY 2026 budget, will enable the military to integrate Symvess into battlefield medical protocols as an off‑the‑shelf, biologically active conduit when autologous vein harvest is not feasible.
Symvess® is the only FDA‑approved human‑derived bioengineered blood vessel, receiving full clearance on December 19 2024. The device has been used in a humanitarian program in Ukraine, where a retrospective study of 16 patients reported 100 % survival, zero amputations, and no conduit infections. The ATEV (acellular tissue‑engineered vessel) received priority designation for vascular trauma from the Secretary of Defense, underscoring its strategic importance for military medicine.
The DoD funding validates Symvess’s clinical value and opens a substantial new market for Humacyte. By enabling procurement through the Defense Logistics Agency’s ECAT system, the company can now supply the device to DoD and VA facilities, expanding its commercial footprint beyond civilian trauma centers. The funding also signals confidence in the technology’s ability to save limbs and lives on the battlefield, positioning Humacyte to capture a larger share of the vascular repair market and strengthen long‑term revenue prospects.
Following the announcement, Humacyte’s stock surged 11.4 %, reflecting investor enthusiasm for the new government contract and the broader market potential. The rally was driven by the clear government endorsement and the expectation of a steady demand stream from military and veteran hospitals.
CEO Laura Niklason said, “America’s brave men and women in uniform deserve the very best care we can provide. This funding will help ensure soldiers have access to cutting‑edge treatments.” She added that the company will accelerate its commercialization strategy and continue to invest in clinical studies to support broader adoption of Symvess.”
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.